Industry Briefs: Feb. 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Apricus Bioscience’s wholly owned subsidiary NexMed (USA) has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio’s Vitaros (alprostadil) drug for treating erectile dysfunction.
The Biomedical Advanced Research and Development Authority has awarded a contract worth up to $67 million for the development of a Tetraphase Antibiotic.
Catalent Pharma Solutions has completed the acquisition of the clinical trials supplies business of Aptuit.
FDA issued a Warning Letter to West-Ward Pharmaceticals for significant violations of cGMP regulations for finished pharmaceuticals.
Mylan plans to change the name of its specialty subsidiary from Dey Pharma to Mylan Specialty.
OncoPep has entered an exclusive license agreement with Dana-Farber for therapeutic multipeptide-vaccine technology for hematologic cancers.
Quintiles plans to expand its commercial services in the Middle East and North Africa region through an agreement with Dayarn Pharma.
Wyeth Pharmaceuticals (now part of Pfizer) seeks $960 million in damages from Sun Pharmaceutical for alleged patent infringement.
People News
Amgen has named Michael Severino senior vice-president of global development and corporate chief medical officer.
Astellas has appointed Charlotte M. E. Kremer as senior vice-president of its global medical affairs organization.
Hospira has appointed Zena G. Kaufman as senior vice-president of quality.
OSO BioPharmaceuticals has named Milton Boyer president of manufacturing.
Patheon has appointed Stuart Grant as executive vice-president and chief financial officer.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
